IBS is a debilitating condition that markedly affects quality of life. The chronic nature, high
prevalence and associated comorbidities contribute to the considerable economic burden of …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

OBJECTIVES: Despite increased prescription of a gluten-free diet for gastrointestinal
symptoms in individuals who do not have celiac disease, there is minimal evidence that …

Abstract Background and Aim: Reduction of short‐chain poorly absorbed carbohydrates
(FODMAPs) in the diet reduces symptoms of irritable bowel syndrome (IBS). In the present …

Preliminary studies indicate that dietary restriction of fermentable short-chain carbohydrates
improves symptoms in irritable bowel syndrome (IBS). Prebiotic fructo-oligosaccharides and …

Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …

Background: Emerging evidence indicates that the consumption of fermentable
oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) may result in …

Background Functional gut symptoms are induced by inclusion and reduced by dietary
restriction of poorly absorbed short‐chain carbohydrates (FODMAPs), but the mechanisms …

Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …